The NRS has published on their blog some results from a recently
concluded study. The study was titled `Structural and biologic changes in the rosacea skin induced by pulse dye laser and intense pulsed light’, and was part funded by the now defunct Rosacea Research Foundation.
Many rosacea sufferers, especially those who suffer from ocular rosacea wonder if they will ever be able to regularly and comfortably wear contact lenses. When your eyes are sore, gritty and blurry would one want to consider trying to apply a contact lens ? I don’t have any
ocular symptoms but I do know that I take it as right to be able to
wear contacts instead of the hassle of glasses.
PAPER: In this article, Contact Lens Wear in The Rosacea Patient (which was mentioned in a recent edition of Rosacea Review), Dr. Mannis lists the factors involved with the successful wearing of contact lenses when you suffer from ocular symptoms.
This article from the DailyMail is offering some warnings about being
too quick to jump on the Melanotan II bandwagon. It is worth
remembering on top of all of the warnings below, that Melanotan
specifically as a rosacea treatment is also something we know very
little about. I think that the combination of rosacea sufferers
desperate for relief, the relative ease of obtaining Melanotan, and the fact that so little is known about its effects, is a recipe for
NEWS PAPER: Pretty pills: The dark side of the latest underground
This recently published blind study suggests that elidel (pimecrolimus)
is no better for rosacea papules and pustules than the vehicle it uses.
A previous study in 2005, Pimecrolimus for treatment of acne rosacea
suggested that elidel could indeed be useful for rosacea, but this
study was not a double blind study – it was not compared to another
PAPER: Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial.
Collagenex has announced that their ongoing trials to find the best
dosage for Incyclinide have discovered that 40mg can cause
PRESS RELEASE: CollaGenex Pharmaceuticals Discontinues 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne